FDA-2026-P-5122

Requests that the FDA declare that an ANDA may be submitted for, Prazosin Hydrochloride Capsules, USP 3 mg and 4 mg, two strength’s that differ from the currently approved RLD, MINIPRESS (Prazosin Hydrochloride) capsules from PFIZER LABORATORIES DIV PFIZER INC., which FDA approved in 1 mg, 2 mg, and 5 mg strengths prior to Jan 1, 1982 under NDA #017442.